In cases of peritoneal dissemination by high-grade adenocarcinoma or with signet-ring cell features (any T, M1b; PMCA/PMCA-SRC), CRS plus HIPEC remains the cornerstone of locoregional therapy but is commonly combined with systemic chemotherapy because of the more aggressive biology and poorer prognosis (36, 37). Here, SRC is linked to adenocarcinoma.